Fmr LLC Acquires 13,324 Shares of OmniAb, Inc. (NASDAQ:OABI)

Fmr LLC increased its holdings in OmniAb, Inc. (NASDAQ:OABI) by 10.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 138,813 shares of the company’s stock after buying an additional 13,324 shares during the period. Fmr LLC owned about 0.12% of OmniAb worth $587,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its holdings in shares of OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after acquiring an additional 194,835 shares during the period. Rice Hall James & Associates LLC boosted its position in OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after purchasing an additional 163,038 shares in the last quarter. Woodstock Corp grew its stake in OmniAb by 5.6% in the third quarter. Woodstock Corp now owns 792,853 shares of the company’s stock valued at $3,354,000 after purchasing an additional 42,310 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in OmniAb by 2.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 787,522 shares of the company’s stock worth $3,331,000 after purchasing an additional 16,219 shares in the last quarter. Finally, Towerview LLC raised its holdings in OmniAb by 2.8% in the third quarter. Towerview LLC now owns 550,000 shares of the company’s stock worth $2,326,000 after purchasing an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on OABI. Benchmark restated a “buy” rating and issued a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th.

OmniAb Stock Performance

Shares of NASDAQ OABI opened at $3.56 on Thursday. OmniAb, Inc. has a fifty-two week low of $3.54 and a fifty-two week high of $6.72. The company has a market cap of $502.73 million, a PE ratio of -5.74 and a beta of -0.14. The business has a 50-day simple moving average of $4.02 and a two-hundred day simple moving average of $4.18.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.